Skip to main content
LTUS logo

Lotus Pharmaceuticals, Inc. (LTUS) Stock Price & Analysis

Educational signal · not a buy or sell recommendation · How to read this

$0.0031 -$0.00143 (-31.57%)
Vol: 881|
Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

Lotus Pharmaceuticals, Inc. (LTUS) trades at $0.0031. Lotus Pharmaceuticals, Inc. (LTUS) is a shell company with no substantial business activities, previously focused on pharmaceutical development and distribution in China. Sector: Financials.

Price as of · Last analyzed: Jun 14, 2026
Lotus Pharmaceuticals, Inc. (LTUS) is a shell company with no substantial business activities, previously focused on pharmaceutical development and distribution in China. It trades on the OTC Other tier, characterized by limited disclosure and liquidity.

Analyst Coverage for LTUS: LTUS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.

No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • MTRI · Metro Inc. · 38 /100
  • DMII · Drugs Made In America Acquisition II Corp. · 49 /100
  • BCSS · Bain Capital GSS Investment Cor · 55 /100

See all scored stocks →

Lotus Pharmaceuticals, Inc. (LTUS) Financial Services Profile

CEOZhong Yi Liu
Employees233
HeadquartersNashville, US
IPO Year2005

Lotus Pharmaceuticals, Inc. operates as a shell company, currently lacking substantial business activities, having historically engaged in pharmaceutical product development and distribution within the People's Republic of China. Headquartered in Nashville, US, the entity trades on the OTC Other tier, reflecting its non-operational status and limited public disclosures.

Data Provenance | Financial Data Quantitative Analysis Analysis: Jun 14, 2026

What Is the Investment Thesis for LTUS?

AI-written as of Jun 14, 2026 — figures and tone reflect the data available then, not today's score.

Lotus Pharmaceuticals, Inc. (LTUS) presents a unique investment profile, primarily defined by its status as a shell company with no substantial business activities. The investment thesis revolves around the inherent optionality of a public shell, rather than the performance of an operating business. With a market capitalization of $0.00 billion and no current revenue-generating operations, the company's intrinsic value is speculative, tied to its potential future use as an acquisition vehicle or a platform for new ventures. The historical focus on pharmaceutical development in China provides a background, but no current operational basis. Key value drivers would emerge only if LTUS were to undergo a significant corporate event, such as a reverse merger with a private operating company seeking a public listing, or if new management were to acquire and re-capitalize the entity for a new business direction. The company's listing on the OTC Other tier implies limited liquidity and disclosure, adding layers of risk. Investors considering LTUS would be speculating on a future strategic transaction that could transform the company from a dormant entity into an active enterprise, rather than on fundamental business growth or profitability. The Beta of -1.64, while a historical metric, offers little insight into future performance given the current operational vacuum.

Based on FMP financials and quantitative analysis

LTUS Key Highlights

AI-written as of Jun 14, 2026 — figures and tone reflect the data available then, not today's score.

Lotus Pharmaceuticals, Inc. currently reports a market capitalization of $0.00 billion, reflecting its status with no substantial business activities.

  • The company's Beta of -1.64 indicates a historical inverse relationship with market movements, though this metric's relevance is limited given its current operational status as a shell company.
  • Despite its inactive business operations, Lotus Pharmaceuticals, Inc. maintains a workforce of 233 employees, headquartered in Nashville, US.
  • Shareholders do not receive a dividend, consistent with a company that has no substantial revenue-generating activities or profitability.
  • The primary operational characteristic is the absence of substantial business activities, a critical factor for any potential investor assessment and indicative of its shell company classification.

Who Are LTUS's Competitors?

LTUS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
MTRI Metro Inc. $15.24 -0.26% $889M 38 5-pillar
DMII Drugs Made In America Acquisition II Corp. $10.26 +0.29% $654M 49 5-pillar
BCSS Bain Capital GSS Investment Cor $10.41 +0.68% $608M 55 5-pillar
CEPF Cantor Equity Partners IV, Inc. $10.32 -0.00% $590M 50 5-pillar
UMAC UMAC $9.61 -4.28% $499M —
NPAC New Providence Acquisition Corp. III $10.59 +0.14% $407M 50 5-pillar
CLBR Colombier Acquisition Corp. $10.03 -0.20% $401M 52 5-pillar
TACO Berto Acquisition Corp. $10.53 +0.10% $395M 56 5-pillar

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are LTUS's Key Strengths?

Existing public listing on the OTC market provides a potential vehicle for future corporate transactions.

  • Established corporate structure and headquarters in Nashville, US, with 233 employees, indicating organizational capacity.
  • Historical experience in the pharmaceutical sector, particularly in China, which could inform future strategic pivots.
  • No current operational liabilities from active business, potentially offering a 'clean slate' for new ventures.

What Are LTUS's Weaknesses?

No substantial business activities, leading to a lack of revenue, profits, and intrinsic operational value.

  • Market capitalization of $0.00 billion reflects its non-operational status and limited investor confidence.
  • Trading on the OTC Other tier, which typically entails limited liquidity and higher investment risk.
  • Unknown disclosure status, potentially limiting investor access to critical financial and operational information.

What Are the Key Risks for LTUS?

Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.

  • The primary risk is the continued absence of substantial business activities, leading to zero revenue and an indefinite period of non-operation.
  • Limited or unknown disclosure status on the OTC Other tier poses significant transparency risks, making it difficult for investors to assess the company's true state.
  • High illiquidity and wide bid-ask spreads on the OTC market could make it challenging for investors to exit positions without significant price impact.
  • Risk of further erosion of market capitalization or even delisting if the company fails to establish an active business or meet minimum listing requirements.
  • Lack of a clear strategic direction or failure to attract a suitable merger partner could prolong its status as a dormant shell company indefinitely.

What Threats Does LTUS Face?

  • Continued lack of substantial business activities leading to potential delisting or further erosion of market value.
  • Inability to attract a suitable merger partner or new business venture, prolonging its dormant status.
  • Regulatory changes impacting OTC markets or shell companies, increasing compliance burdens or limiting utility.
  • Competition from other public shell companies that may offer more attractive structures or cleaner historical records.

What Are LTUS's Competitive Advantages?

  • Currently, Lotus Pharmaceuticals, Inc. possesses no active competitive advantages or 'moat' due to its lack of substantial business activities.
  • Historically, in the pharmaceutical sector, potential moats could have included intellectual property, regulatory approvals, or established distribution networks in China.
  • As a shell company, its 'moat' is limited to its existing public listing and corporate structure, which can offer a faster route to market for a private entity than a traditional IPO.
  • The company's historical background might offer some brand recognition or a network of contacts if it were to re-enter the pharmaceutical space, but this is speculative.
  • The lack of active operations means there are no current barriers to entry for competitors in any market segment.

What Does LTUS Do?

Lotus Pharmaceuticals, Inc. (LTUS) is a corporate entity currently characterized by the absence of substantial business activities. Headquartered in Nashville, Tennessee, the company's operational history indicates a previous focus on the pharmaceutical sector, specifically involving the development, production, and distribution of pharmaceutical products within the People's Republic of China. This historical engagement suggests a background in a highly regulated and capital-intensive industry, requiring expertise in research and development, manufacturing, and complex supply chain management. However, the company has since transitioned to a non-operational status, effectively functioning as a shell company in the present market. This means that while the corporate structure, including its public listing on the OTC Other tier, remains intact, there are no active revenue-generating operations or ongoing business ventures. The company maintains a workforce of 233 employees, which suggests a residual corporate infrastructure despite the lack of active business. The evolution from a pharmaceutical developer to a non-operating entity implies a significant strategic shift or cessation of previous activities, leaving the company's future direction contingent on potential new ventures, acquisitions, or strategic pivots. Its current market position is defined by its status as a public shell, offering a potential vehicle for a reverse merger or new business initiatives, rather than through active competition in any specific industry segment.

What Products and Services Does LTUS Offer?

  • Currently, Lotus Pharmaceuticals, Inc. has no substantial business activities.
  • It maintains a corporate structure as a publicly listed entity on the OTC Other tier.
  • Historically, the company focused on the development of pharmaceutical products.
  • Its past operations included the production and distribution of pharmaceuticals.
  • Previous business activities were primarily conducted within the People's Republic of China.
  • The company functions as a shell, potentially available for future corporate transactions like mergers or acquisitions.
  • It retains a headquarters in Nashville, Tennessee, and a workforce of 233 employees despite its non-operational status.

How Does LTUS Make Money?

  • Currently, Lotus Pharmaceuticals, Inc. has no active business model as it lacks substantial business activities.
  • Historically, its business model involved the development, production, and distribution of pharmaceutical products, likely generating revenue through product sales.
  • As a shell company, its potential future 'business model' could involve facilitating a reverse merger, where a private company merges into LTUS to gain public market access.
  • Another theoretical model could be the acquisition of new assets or an operating business, transforming it into an active company.
  • Its current 'value proposition' lies in its status as a public vehicle, rather than through ongoing operations or revenue generation.

What Industry Does LTUS Operate In?

Lotus Pharmaceuticals, Inc. operates within the 'Shell Companies' industry, a sub-segment of the broader Financial Services sector. This industry is characterized by entities that possess a corporate structure and often a public listing, but lack active business operations or significant assets. Shell companies typically exist as vehicles for future mergers, acquisitions, or new business ventures, often serving as a shortcut for private companies to go public through a reverse merger. The market for shell companies is driven by the demand for streamlined access to public capital markets, particularly for private entities seeking liquidity or growth capital without the extensive process of a traditional IPO. Unlike active operating companies, LTUS does not compete on products or services but rather on its structural attributes and potential as a corporate vehicle. The competitive landscape for shell companies involves other publicly traded non-operating entities, where factors like clean capital structure, historical liabilities, and disclosure status can influence attractiveness to potential acquirers. The industry's trends are often linked to overall capital market activity and the appetite for alternative public listing methods.

Who Are LTUS's Key Customers?

  • Currently, Lotus Pharmaceuticals, Inc. has no active customer base due to its lack of substantial business activities.
  • Historically, its customers would have been healthcare providers, pharmacies, or distributors within the People's Republic of China for its pharmaceutical products.
  • In its current state as a shell company, potential 'customers' could be private companies seeking a public listing via a reverse merger.
  • Future customers would depend entirely on any new business ventures or acquisitions the company might undertake.
  • The 233 employees are internal stakeholders, not external customers generating revenue.
Model self-rating on this text: 63% (not a measure of the evidence) Updated: Jun 14, 2026

Research confidence

Low

Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.

  • ● Scoring coverage unknown
  • ● No usable price
  • ● No filing on record
  • ● No analyst coverage

Company Profile

Lotus Pharmaceuticals, Inc. operates in the Shell Companies industry within the Financial Services sector. It is headquartered in Irvine, United States.

F-Score 1/9

Financial Health

Lotus Pharmaceuticals, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

LTUS Latest News

No recent news available for LTUS.

LTUS Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for LTUS.

Price Targets

Wall Street price target analysis for LTUS.

LTUS MoonshotScore

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for LTUS; grades run from A+ (80-100) to F (below 30).

Leadership: Zhong Yi Liu

Chief Executive Officer

Zhong Yi Liu serves as the Chief Executive Officer of Lotus Pharmaceuticals, Inc., overseeing a workforce of 233 employees. While specific details regarding Mr. His role involves managing the existing corporate structure of a company that currently lacks substantial business activities, implying a focus on corporate governance, strategic planning for future endeavors, or maintaining the company's public listing status. His tenure is marked by the company's current status as a shell entity.

Track Record: Under Zhong Yi Liu's leadership, Lotus Pharmaceuticals, Inc. has maintained its corporate structure and public listing on the OTC Other tier, despite having no substantial business activities. Key aspects of his track record include managing the company's 233 employees and overseeing its operational presence in Nashville, US. While specific achievements related to active business growth are not applicable given the company's current status, his role involves navigating the complexities of a non-operating public entity. Any future strategic decisions, such as potential mergers, acquisitions, or pivots into new business ventures, would fall under his purview, marking significant milestones for the company's future direction.

LTUS OTC Market Information

Lotus Pharmaceuticals, Inc. trades on the OTC Other tier, which is the lowest and most speculative tier of the OTC Markets Group. Unlike companies listed on national exchanges like NYSE or NASDAQ, which have stringent listing requirements for financial health and corporate governance, OTC Other companies face minimal disclosure requirements. This tier is typically home to shell companies, defunct companies, or those with limited public information. It signifies a higher risk profile for investors due to the lack of transparency and regulatory oversight compared to higher OTC tiers like OTCQX or OTCQB, which have more robust reporting standards. The 'OTC Other' designation indicates that the company does not meet the criteria for any of the higher tiers, often due to a lack of current information or active business operations.

  • OTC Tier: OTC Other
Liquidity: Trading on the OTC Other tier, Lotus Pharmaceuticals, Inc. likely experiences very limited liquidity. This means that the volume of shares traded daily is typically low, and the bid-ask spread (the difference between the highest price a buyer is willing to pay and the lowest price a seller is willing to accept) can be wide. Such conditions make it difficult for investors to buy or sell shares quickly without significantly impacting the stock price. The lack of substantial business activities and unknown disclosure status further contribute to this illiquidity, as there is little fundamental news or operational performance to drive trading interest. Investors should anticipate challenges in executing trades efficiently and potentially face significant price volatility.
OTC Risk Factors:
  • Limited or unknown public disclosure, making it difficult to assess financial health, operations, or management.
  • Extremely low liquidity, leading to wide bid-ask spreads and difficulty in buying or selling shares without price impact.
  • High susceptibility to fraud and manipulation due to minimal regulatory oversight and lack of transparency.
  • Potential for delisting or further market value erosion if the company remains without substantial business activities.
  • Absence of a clear business plan or revenue-generating operations, making future prospects highly speculative.
Due Diligence Checklist:
  • Verify any available financial statements, even if unaudited or outdated, to understand historical financial health.
  • Research any corporate actions, such as reverse mergers or name changes, that may have occurred.
  • Investigate the background and track record of current management and board members beyond provided information.
  • Assess the company's capital structure, including outstanding shares, warrants, and convertible debt.
  • Determine if there are any known assets, intellectual property, or historical liabilities from previous operations.
  • Evaluate the potential for a reverse merger or acquisition by a legitimate operating company.
  • Monitor for any news or announcements regarding a change in business direction or new management.
Legitimacy Signals:
  • Retention of a physical headquarters in Nashville, US, and a stated employee count of 233.
  • Historical focus on a legitimate industry (pharmaceuticals) in a specific region (China).
  • Existence of a named CEO, Zhong Yi Liu, indicating an active management presence.
  • Maintenance of a public listing, even on the OTC Other tier, suggesting a corporate structure is still in place.
  • Any future announcements of a clear business plan, new management, or a legitimate merger partner would be strong signals.

Common Questions About LTUS (Financials)

What does Lotus Pharmaceuticals, Inc. do in its current state?

In its current state, Lotus Pharmaceuticals, Inc. (LTUS) has no substantial business activities. It functions as a shell company, meaning it possesses a corporate structure, a public listing on the OTC Other tier, and a headquarters in Nashville, Tennessee, along with 233 employees, but it does not engage in any active revenue-generating operations.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • The 'no substantial business activities' constraint made several sections, particularly 'investmentThesis' and 'growthOpportunities', challenging to meet word counts without speculation. I focused on the implications of being a shell company and theoretical opportunities.
  • The absence of FMP PEER TICKERS resulted in an empty 'competitors' array as per instructions.
  • The 'Unknown' disclosure status for OTC analysis was directly used.
  • Word counts for specific sections were strictly adhered to, sometimes requiring careful phrasing to elaborate on the implications of a non-operating entity.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis

Stock Deep Dives